Vantage logo

The trigger for a Seagen buyout

Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.

Vantage logo

The lowdown on high blood pressure

After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.

Vantage logo

Amylyx faces an uphill battle

Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?